Volasertib program presented at Society of Hematology and Oncology (SOHO) session
Volasertib AML Phase 2 trial expected to begin in coming months
FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) — Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing novel cancer therapies identified by its predictive medicine platform (PMP), today announced that it will present Phase 2 program overviews and additional data from preclinical studies evaluating volasertib in acute myeloid leukemia (AML) at the Society of Hematology and Oncology 12th Annual Meeting (SOHO 2024), taking place on September 4th.Number-7Number 2024.
|
Presentation details: |
|
|
Poster: |
Resurgence of the Polo-like Kinase 1 (PLK1) Inhibitor Volasertib in Relapsed/Refractory Acute Myeloid Leukemia |
|
author: |
G. Michaelson, S. Huston, C. Leonardi, C. Gu, M. Lacher, J. Wagner. |
|
Poster Session: |
Wednesday, September 4Number 6:15 PM CDT |
About volasertib
Volasertib is a PLK-1 inhibitor with proven efficacy in other tumor types with significant unmet medical need, including AML and solid tumors. Building on volasertib’s performance in the PMP, a key and unique step in Notable’s targeted in-licensing strategy and decision-making, Notable plans to use the PMP to predict which patients will respond to volasertib prior to treatment, selectively enroll and treat predicted responders, with the goal of improving volasertib response rates and overall patient outcomes, and expediting the remaining clinical development of volasertib. Volasertib was originally developed and manufactured by Boehringer Ingelheim and previously received Breakthrough Therapy Designation from the FDA. Notable has licensed volasertib and has exclusive worldwide development and commercialization rights, except for certain rare pediatric cancers.
About Notable Labs, Ltd.
Notable Labs, Ltd. is a clinical-stage platform therapeutics company developing predictive medicine for cancer patients. Through its proprietary predictive medicine platform (PMP), Notable aims to predict whether a patient is likely to respond to a specific therapeutic drug. The PMP is designed to identify and select clinically responsive patients prior to treatment, allowing them to fast-track clinical development. By continually advancing and expanding the scope of its PMP across diseases and predicted medical outcomes, Notable aims to be a leader in predictive medicine and revolutionize the way patients seek and receive the treatments that are best for them.
Notable believes that the use of PMPs also enables a more targeted, less risky in-licensing strategy to increase the likelihood of success and realize a product’s medical impact and commercial value faster than traditional drug development. By transforming traditional standards of care, Notable aims to dramatically positively impact patients and the medical community. Notable is headquartered in Foster City, California.
For more information, visit our website at https://notablelabs.com/ and follow us at @notablelabs.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, but are not limited to, express or implied statements regarding Notable’s future operations and objectives, the potential benefits of Notable’s therapeutic candidates or platform technology, the timing of clinical milestones for Notable’s therapeutic candidates, the company’s cash runway, and other statements that are not historical facts. All statements other than historical facts contained in this communication are forward-looking statements. These forward-looking statements speak only as of the date they were first issued and are based on expectations, estimates, forecasts and projections as of that date, as well as management’s beliefs and assumptions. Forward-looking statements are subject to a number of risks and uncertainties, many of which relate to factors or circumstances beyond Notable’s control. Notable’s actual results may differ materially from those expressed or implied by the forward-looking statements due to a number of factors. Factors include, but are not limited to, (i) risks associated with the clinical development and regulatory approval of product candidates, including uncertainties related to Notable’s platform technology and possible delays in the initiation, enrollment and completion of clinical trials; (ii) risks associated with Notable’s inability to raise sufficient additional capital to continue to advance these product candidates and preclinical programs; (iii) uncertainties regarding the achievement of successful clinical results for the product candidates and potential unanticipated costs resulting therefrom; (iv) risks associated with the failure to realize value from the product candidates and preclinical programs in or expected to be developed given the inherent risks and difficulties associated with successfully bringing product candidates to market; (v) risks associated with Notable’s future financial and operating results, including its ability to generate revenues; (vi) Notable’s ability to retain key personnel; and (vii) Notable’s ability to manage the requirements of being a public company. (viii) uncertainties related to the Israel-Hamas war, (ix) Notable’s ability to obtain orphan drug designation and related benefits for any of its drug candidates, (x) Notable’s inability to obtain regulatory approval for any of its drug candidates, and (xi) changes or additions to international, federal, state or local legal requirements, such as changes or additions to tax laws and rates, drug regulations and other regulations. As a result of these risks and uncertainties, actual results and the timing of events may differ materially from those anticipated in such forward-looking statements. These and other risks and uncertainties are more fully described in periodic filings with the Securities and Exchange Commission (SEC), including the factors described in the “Risk Factors” section of Notable Labs, Ltd.’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC, and other subsequent filings with the SEC. You should not place undue reliance on these forward-looking statements, which speak only as of the date hereof or as of the date indicated in the forward-looking statements. Notable expressly disclaims any obligation or undertaking to publicly release updates or revisions to any forward-looking statements contained herein to reflect any change in expectations with respect thereto, or any change in events, conditions or circumstances on which any such statement is based.
contact address:
Investor Relations:
Daniel Ferry
Life Sciences Advisor
+1 (617) 430-7576
danielle@lifesciadvisors.com
